Xiao ZY, Wu W, Eagleton N, Chen HQ, Shao J, Teng H, Liu TH, Jiang ZM, Yao HR. Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin. World J Gastroenterol 2010; 16(1): 112-118 [PMID: 20039457 DOI: 10.3748/wjg.v16.i1.112]
Corresponding Author of This Article
He-Rui Yao, Associate Professor, Department of Oncology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, 107 West Yanjiang Road, Guangzhou 510120, Guangdong Province, China. yaoherui@163.com
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 7, 2010; 16(1): 112-118 Published online Jan 7, 2010. doi: 10.3748/wjg.v16.i1.112
Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin
Zhi-Yu Xiao, Wei Wu, Navada Eagleton, Huan-Qing Chen, Jing Shao, Hong Teng, Tian-Hao Liu, Zhi-Min Jiang, He-Rui Yao
Zhi-Yu Xiao, Wei Wu, Huan-Qing Chen, Jing Shao, Department of Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
Navada Eagleton, Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas 77843, United States
Hong Teng, Tian-Hao Liu, Zhi-Min Jiang, He-Rui Yao, Department of Oncology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
Author contributions: Xiao ZY and Wu W contributed equally and performed the majority of experiments; Eagleton N performed statistical analysis and was involved in editing the manuscript; Chen HQ, Shao J, Teng H, Liu TH and Jiang ZM performed part of experiments; Xiao ZY and Yao HR designed the study and wrote the manuscript; Yao HR also provided financial support for this work.
Supported by Research grants from the Science and Technology Foundation of Guangdong Province, No. 2006B36002010, 2008B030301092, 2009B030801005; the Foundation of Health Department of Guangdong Province, No. A2005226; the foundation of Guangzhou Science and Technology Bureau, No. 2009Y-C011-1; the Natural Science Foundation of Guangdong Province, No. 7001592; and the National Natural Science Foundation of China, No. 30973505
Correspondence to: He-Rui Yao, Associate Professor, Department of Oncology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, 107 West Yanjiang Road, Guangzhou 510120, Guangdong Province, China. yaoherui@163.com
Telephone: +86-20-81332107 Fax: +86-20-81332853
Received: October 5, 2009 Revised: November 10, 2009 Accepted: November 17, 2009 Published online: January 7, 2010
Abstract
AIM: To investigate whether silencing Fas-associated phosphatase 1 (FAP-1) expression enhances the efficiency of chemotherapy for colon carcinoma with oxaliplatin.
METHODS: Expression of FAP-1 in mRNA and protein was detected by reverse transcription polymerase chain reaction (RT-PCR) and flow cytometry. Small interfering RNA (siRNA) was designed according to the FAP-1 mRNA sequence. Cell proliferation was evaluated by methyl thiazolyl tetrazolium (MTT) assay. Anenxin V- and propidine iodine (PI) were assayed by flow cytometry for the detection of apoptosis.
RESULTS: The expression of FAP-1 was increased in SW480 cells after chemotherapy with oxaliplatin. Transfection of FAP-1 siRNA into SW480 cells silenced the expression of FAP-1 and consequently abolished the inhibitory function of Fas/FasL-mediated apoptosis pathway, thus increasing the efficacy of chemotherapy for colon carcinoma with oxaliplatin.
CONCLUSION: RNA interference combined with conventional chemotherapy is more effective against colon cancer.
